1. Home
  2. DMAC vs GFR Comparison

DMAC vs GFR Comparison

Compare DMAC & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • GFR
  • Stock Information
  • Founded
  • DMAC 2000
  • GFR 2018
  • Country
  • DMAC United States
  • GFR Canada
  • Employees
  • DMAC N/A
  • GFR N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • GFR
  • Sector
  • DMAC Health Care
  • GFR
  • Exchange
  • DMAC Nasdaq
  • GFR Nasdaq
  • Market Cap
  • DMAC 310.1M
  • GFR 330.9M
  • IPO Year
  • DMAC N/A
  • GFR N/A
  • Fundamental
  • Price
  • DMAC $6.96
  • GFR $4.74
  • Analyst Decision
  • DMAC Strong Buy
  • GFR
  • Analyst Count
  • DMAC 3
  • GFR 0
  • Target Price
  • DMAC $12.33
  • GFR N/A
  • AVG Volume (30 Days)
  • DMAC 343.5K
  • GFR 40.5K
  • Earning Date
  • DMAC 11-12-2025
  • GFR 11-13-2025
  • Dividend Yield
  • DMAC N/A
  • GFR N/A
  • EPS Growth
  • DMAC N/A
  • GFR N/A
  • EPS
  • DMAC N/A
  • GFR 2.05
  • Revenue
  • DMAC N/A
  • GFR $516,308,125.00
  • Revenue This Year
  • DMAC N/A
  • GFR N/A
  • Revenue Next Year
  • DMAC N/A
  • GFR $27.03
  • P/E Ratio
  • DMAC N/A
  • GFR $2.30
  • Revenue Growth
  • DMAC N/A
  • GFR N/A
  • 52 Week Low
  • DMAC $3.19
  • GFR $3.81
  • 52 Week High
  • DMAC $7.49
  • GFR $8.16
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 58.60
  • GFR N/A
  • Support Level
  • DMAC $6.75
  • GFR N/A
  • Resistance Level
  • DMAC $7.13
  • GFR N/A
  • Average True Range (ATR)
  • DMAC 0.28
  • GFR 0.00
  • MACD
  • DMAC -0.06
  • GFR 0.00
  • Stochastic Oscillator
  • DMAC 50.00
  • GFR 0.00

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About GFR Greenfire Resources Ltd.

Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.

Share on Social Networks: